IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0267504.html
   My bibliography  Save this article

Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator

Author

Listed:
  • Lucía Romero-Pinel
  • Laura Bau
  • Elisabet Matas
  • Isabel León
  • Roser Juvany
  • Ramon Jódar
  • Antonio Martínez-Yélamos
  • Sergio Martínez-Yélamos

Abstract

Background: The efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS) are well known; however, owing to their high costs, determining real-world outcomes is essential to evaluate the cost-effectiveness of different therapeutic strategies. This study aimed to investigate the variability in the annual cost of DMTs associated with a relapse-free patient in a representative population cohort of relapsing-remitting MS (RRMS), and whether this could serve as an appropriate health indicator. Methods: We analyzed the patients followed up in our MS clinic during the years 2016 and 2019, and selected patients belonging to our health district diagnosed with RRMS. The treatment cost associated with a relapse-free patient was the ratio between the total cost of DMTs and the number of relapse-free patients, treated and not treated, during the year of the study. Results: A total of 158 patients with RRMS in 2016 and 183 in 2019 were included in our study. In 2016, 101 patients with RRMS (63.9%) received treatment with DMTs and 120 patients (75.9%) remained relapse-free. The mean cost of DMTs per patient in 2016 was €7414.3 (95% confidence interval [CI]: 6325.2–8503.4) considering all the patients (treated and not treated). In 2019, 126 patients (68.9%) received DMTs and 151 patients (82.5%) remained relapse-free. The mean cost of DMTs per patient in 2019 was €6985.4 (95% CI: 5986.9–7983.9) considering all the patients. The cost per year of DMTs to achieve a relapse-free patient was €9762.2 in 2016 and €8465.8 in 2019. Conclusions: The treatment cost per year to achieve a relapse-free patient was stable during successive measurements in the same population. Therefore, it may be considered a good real-world health indicator for patients with RRMS treated with DMTs.

Suggested Citation

  • Lucía Romero-Pinel & Laura Bau & Elisabet Matas & Isabel León & Roser Juvany & Ramon Jódar & Antonio Martínez-Yélamos & Sergio Martínez-Yélamos, 2022. "Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator," PLOS ONE, Public Library of Science, vol. 17(4), pages 1-10, April.
    • Handle: RePEc:plo:pone00:0267504
    DOI: 10.1371/journal.pone.0267504
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267504
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0267504&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0267504?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Olivia Ernstsson & Hanna Gyllensten & Kristina Alexanderson & Petter Tinghög & Emilie Friberg & Anders Norlund, 2016. "Cost of Illness of Multiple Sclerosis - A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-25, July.
    2. Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Carmelo A. Juárez-Castelló, 2018. "Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?," PharmacoEconomics, Springer, vol. 36(7), pages 733-743, July.
    3. Andersson, Emelie & Svensson, Johanna & Persson, Ulf & Lindgren, Peter, 2020. "Risk sharing in managed entry agreements—A review of the Swedish experience," Health Policy, Elsevier, vol. 124(4), pages 404-410.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Rositsa Koleva-Kolarova & James Buchanan & Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & Maureen Rutten-van Mölken & László Szilberhorn & Tamás Zelei & Balázs Nagy & Sarah Wordsworth & Apos, 2022. "Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options," Applied Health Economics and Health Policy, Springer, vol. 20(4), pages 501-524, July.
    3. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    4. Fernando Gracia & Mario Larreategui & Gaudencio Rodríguez & Aaron Benzadón & Michelle Ortiz & Divian Morales & Claudia Domínguez & Rosa Enith Carrillo & Carlos Valderrama & Luís Lizán & Blas Armién, 2018. "Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    5. B. Rodríguez-Sánchez & S. Daugbjerg & L. M. Peña-Longobardo & J. Oliva-Moreno & I. Aranda-Reneo & A. Cicchetti & J. López-Bastida, 2023. "Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 247-277, March.
    6. Jalal Dahham & Rana Rizk & Ingrid Kremer & Silvia M. A. A. Evers & Mickaël Hiligsmann, 2021. "Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review," PharmacoEconomics, Springer, vol. 39(7), pages 789-807, July.
    7. Mennini, Francesco Saverio & Gitto, Lara, 2022. "Approaches to Estimating Indirect Costs in Healthcare: Motivations for Choice," MPRA Paper 112129, University Library of Munich, Germany.
    8. Tomasz Zaprutko & Dorota Kopciuch & Krzysztof Kus & Piotr Merks & Monika Nowicka & Izabela Augustyniak & Elżbieta Nowakowska, 2017. "Affordability of medicines in the European Union," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-13, February.
    9. Alfredo Palacios & Carlos Rojas-Roque & Lucas González & Ariel Bardach & Agustín Ciapponi & Claudia Peckaitis & Andres Pichon-Riviere & Federico Augustovski, 2021. "Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review," PharmacoEconomics, Springer, vol. 39(5), pages 485-502, May.
    10. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.
    11. Korinna Karampampa & Hanna Gyllensten & Fei Yang & Chantelle Murley & Emilie Friberg & Jan Hillert & Kristina Alexanderson, 2020. "Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden," PharmacoEconomics - Open, Springer, vol. 4(1), pages 91-103, March.
    12. Jalal Dahham & Ingrid Kremer & Mickaël Hiligsmann & Kamal Hamdan & Abdallah Nassereddine & Silvia M. A. A. Evers & Rana Rizk, 2023. "Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 31-38, January.
    13. Luana Nice da Silva Oliveira & Alexander Itria & Erika Coutinho Lima, 2019. "Cost of illness and program of dengue: A systematic review," PLOS ONE, Public Library of Science, vol. 14(2), pages 1-15, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0267504. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.